MedPage Today on MSN
Anticoagulant Reversal Drug Pulled From U.S. Market
In May 2018, andexanet was granted accelerated approval as the sole antidote on the market for the DOACs rivaroxaban (Xarelto ...
Varmx BV has raised €30 million (US$32 million) in an extension to its series B to fund preparations for the pivotal trial of VMX-C001, a modified recombinant factor X that acts as a universal ...
LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised ...
(MENAFN- EIN Presswire) EINPresswire/ -- The global anticoagulant reversal drugs market is poised for significant expansion over the next decade, driven by increasing use of oral anticoagulants, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results